Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Mackey
John R
JR
Department of Oncology, University of Alberta, Alberta, Canada. johnmack@cancerboard.ab.ca
Galmarini
Carlos M
CM
Graham
Kathryn A
KA
Joy
Anil A
AA
Delmer
Alain
A
Dabbagh
Laith
L
Glubrecht
Darryl
D
Jewell
Lawrence D
LD
Lai
Raymond
R
Lang
Thack
T
Hanson
John
J
Young
James D
JD
Merle-Béral
Helene
H
Binet
Jacques L
JL
Cass
Carol E
CE
Dumontet
Charles
C
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D033703:Nucleoside Transport Proteins / Q000235:genetics* / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D026901:Membrane Transport Proteins; D033703:Nucleoside Transport Proteins; D012333:RNA, Messenger; C065171:cif nucleoside transporter; D014740:Vidarabine; C024352:fludarabine